journal
https://read.qxmd.com/read/38369388/medication-based-comorbidity-measures-and-prostate-cancer-treatment-selection
#41
JOURNAL ARTICLE
Tenaw Tiruye, Michael O'Callaghan, Liesel M FitzGerald, Kim Moretti, Alex Jay, Braden Higgs, Ganessan Kichenadasse, Gillian Caughey, David Roder, Kerri Beckmann
INTRODUCTION: We aimed to assess the association between comorbidities and prostate cancer management. PATIENTS AND METHODS: We studied 12,603 South Australian men diagnosed with prostate cancer between 2003 and 2019. Comorbidity was measured one year prior to prostate cancer diagnosis using a medication-based comorbidity index (Rx-Risk). Binomial logistic regression analyses were used to assess the association between comorbidities and primary treatment selection (active surveillance, radical prostatectomy (RP), external beam radiotherapy (EBRT) with or without androgen deprivation therapy (ADT), brachytherapy, ADT alone, and watchful waiting (WW))...
February 1, 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38369387/married-status-affects-rates-of-treatment-and-mortality-in-male-and-female-renal-cell-carcinoma-patients-across-all-stages
#42
JOURNAL ARTICLE
Carolin Siech, Simone Morra, Lukas Scheipner, Andrea Baudo, Letizia M I Jannello, Mario de Angelis, Jordan A Goyal, Zhe Tian, Fred Saad, Shahrokh F Shariat, Nicola Longo, Luca Carmignani, Ottavio de Cobelli, Sascha Ahyai, Alberto Briganti, Philipp Mandel, Luis A Kluth, Felix K H Chun, Pierre I Karakiewicz
INTRODUCTION: The association between treatment rates and cancer specific mortality (CSM) according to married status in male and female clear cell renal cell carcinoma (ccRCC) patients across all stages is unknown. PATIENT AND METHODS: Using the Surveillance, Epidemiology, and End Results database (2004-2020), ccRCC patients were stratified according to married status (married vs. unmarried). Logistic regression models addressed treatment rates; Cox regression models addressed CSM rates...
February 1, 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38101983/cabozantinib-in-the-routine-management-of-renal-cell-carcinoma-a-systematic-literature-review-of-real-world-evidence
#43
REVIEW
Marine Gross-Goupil, Lubomir Bodnar, Matthew T Campbell, Agnieszka Michael, Balaji Venugopal, Jakub Żołnierek, Pascale Dutailly, Giuseppe Procopio, Laurence Albiges
Real-world cabozantinib use has increased since its approval to treat patients with advanced renal cell carcinoma (RCC) in 2016. We reviewed cabozantinib use in real-world clinical practice and compared outcomes with pivotal cabozantinib randomized control trials (RCTs). This PRISMA-standard systematic literature review evaluated real-world effectiveness and tolerability of cabozantinib in patients with RCC (PROSPERO registration: CRD42021245854). Systematic MEDLINE, Embase, and Cochrane database searches were conducted on November 2, 2022...
February 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/37598012/neoadjuvant-chemotherapy-prior-to-radical-cystectomy-for-muscle-invasive-bladder-cancer-with-variant-histology-a-systematic-review-and-meta-analysis-of-survival-outcomes-and-pathological-features
#44
JOURNAL ARTICLE
Do Kyung Kim, Jae Heon Kim, Jun Young Park, Yong Nam Gwon, Ki Min Kim, Won Jae Yang, Seung Whan Doo, Yun Seob Song
PURPOSE: To conduct systematic review and meta-analysis to evaluate effects of neoadjuvant chemotherapy (NAC) on survival and histopathological outcomes of variant histology (VH) of urothelial carcinoma (UC) of bladder. METHODS: This systematic review was registered in PROSPERO (CRD42023389115). Literature search was conducted in PubMed/Medline, Embase, and Cochrane Library for studies published up to January 2023. Population, intervention, comparator, outcome, and study design were as follows: bladder cancer patients with VH (population), neoadjuvant chemotherapy (intervention), radical cystectomy only (comparators), oncological survival and pathologic response (outcomes), and retrospective or prospective (study design)...
February 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38278656/corrigendum
#45
(no author information available yet)
No abstract text is available yet for this article.
January 25, 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38402090/carboplatin-in-metastatic-castrate-resistant-prostate-cancer-a-retrospective-study-of-heavily-pretreated-patients-compact
#46
JOURNAL ARTICLE
Lara Pemberton, Connor Allen, Eleanor Handel, Andrew Weickhardt, Jeremy Shapiro, Ben Tran, Renea A Taylor, Gail P Risbridger, David W Pook
INTRODUCTION: Many clinicians consider carboplatin monotherapy in advanced castrate-resistant prostate cancer (CRPC) patients who have progressed through all available hormonal and standard chemotherapy treatment options, despite the limited evidence to justify its use. PATIENTS AND METHODS: This retrospective analysis aimed to evaluate the use of carboplatin monotherapy in patients with refractory prostate cancer in Australia. Efficacy (PSA response, duration, and survival) as well as toxicity was evaluated...
January 22, 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38383173/urinary-exosomal-mir-17-5p-accelerates-bladder-cancer-invasion-by-repressing-its-target-gene-arid4b-and-regulating-the-immune-microenvironment
#47
JOURNAL ARTICLE
Hejia Yuan, Tianqi Wang, Peng Peng, Zhunan Xu, Fan Feng, Yuanshan Cui, Jian Ma, Jitao Wu
BACKGROUND: Urothelial bladder cancer (BCa) is a common malignant tumor of the urinary system. It has been identified that exosomal miRNAs contribute to the development of BCa. However, its significance and mechanism in the malignant biological behavior of BCa remain unclear. In this study, the influence of exosomal miRNAs on BCa progression was investigated. METHODS: High-throughput sequencing was conducted to analyze the microRNA-expression profile in urinary exosomes to screen out the key miRNA of muscle-invasive bladder cancer (MIBC)...
January 22, 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38369389/incidental-coronary-arterial-calcification-for-cardiovascular-risk-assessment-in-men-with-prostate-cancer-undergoing-pet-ct-imaging
#48
JOURNAL ARTICLE
Preet A Shaikh, Avira Som, Elena Deych, Alison J Deng, Melissa A Reimers, Brian C Baumann, Eric H Kim, Daniel J Lenihan, Kathleen W Zhang
BACKGROUND: Cardiovascular (CV) disease is common among men with prostate cancer and the leading cause of death in this population. There is a need for CV risk assessment tools that can be easily implemented in the prostate cancer treatment setting. METHODS: Consecutive patients who underwent positron emission tomography/computed tomography (PET/CT) for recurrent prostate cancer at a single institution from 2012 to 2017 were identified retrospectively. Clinical data and coronary calcification on nongated CT imaging were obtained...
January 22, 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38342659/a-panel-based-mutational-signature-of-mismatch-repair-deficiency-is-associated-with-durable-response-to-pembrolizumab-in-metastatic-castration-resistant-prostate-cancer
#49
JOURNAL ARTICLE
Daniel Boiarsky, Doga C Gulhan, Hunter Savignano, Gitanjali Lakshminarayanan, Heather M McClure, Rebecca Silver, Michelle S Hirsch, Lynette M Sholl, Atish D Choudhury, Guruprasad Ananda, Peter J Park, Alok K Tewari, Jacob E Berchuck
INTRODUCTION/BACKGROUND: Immune checkpoint inhibitors (ICIs) have limited efficacy in prostate cancer (PCa). Better biomarkers are needed to predict responses to ICIs. We sought to demonstrate that a panel-based mutational signature identifies mismatch repair (MMR) deficient (MMRd) PCa and is a biomarker of response to pembrolizumab. PATIENTS AND METHODS: Clinico-genomic data was obtained for 2664 patients with PCa sequenced at Dana-Farber Cancer Institute (DFCI) and Memorial Sloan Kettering (MSK)...
January 20, 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38336572/the-prognostic-value-of-tumor-infiltrating-lymphocytes-after-radical-cystectomy-for-bladder-cancer-a-systematic-review-and-meta-analysis
#50
REVIEW
Tatsushi Kawada, Takafumi Yanagisawa, Pawel Rajwa, Reza Sari Motlagh, Hadi Mostafaei, Fahad Quhal, Ekaterina Laukhtina, Maximilian Pallauf, Frederik König, Benjamin Pradere, Motoo Araki, Yasutomo Nasu, Shahrokh F Shariat
BACKGROUND: We aimed to assess the prognostic value of tumor infiltrating lymphocytes (TILs) in patients with bladder cancer (BC) after radical cystectomy (RC). MATERIALS AND METHODS: We searched Pubmed, Web of Science and Scopus in April 2022 to identify studies assessing the prognostic value of TILs, including a subset of lymphocytes (eg, CD3, CD8, FOXP3), after RC. The endpoints were overall survival and recurrent free survival. Subgroup analyses were performed based on the evaluation method for TILs (ie, CD3, CD8, FOXP3, HE staining)...
January 17, 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38281878/association-between-kidney-function-and-outcomes-following-immune-checkpoint-inhibitor-based-combination-therapy-in-patients-with-advanced-renal-cell-carcinoma
#51
JOURNAL ARTICLE
Hiroki Ishihara, Yuki Nemoto, Hidekazu Tachibana, Takashi Ikeda, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto, Tsunenori Kondo, Toshio Takagi
BACKGROUND: It remains unclear whether kidney function affects outcomes following immune checkpoint inhibitor (ICI)-based combination therapy for advanced renal cell carcinoma (RCC). METHODS: We retrospectively evaluated data of 167 patients with advanced RCC, including 98 who received ICI dual combination therapy (ie, immunotherapy [IO]-IO) and 69 who received ICI combined with tyrosine kinase inhibitor (TKI) (ie, IO-TKI). In each regimen, treatment profiles were assessed according to the grade of chronic kidney disease (CKD) as defined by the KDIGO 2012 criteria...
January 15, 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38278655/surveillance-or-dynamic-sentinel-lymph-node-biopsy-in-low-risk-clinically-n0-penile-squamous-cell-carcinoma-single-institution-real-world-data
#52
JOURNAL ARTICLE
Sebastiano Nazzani, Mario Catanzaro, Martina Bruniera, Tullio Torelli, Alberto Macchi, Silvia Stagni, Antonio Tesone, Carlo Silvani, Tommaso Ceccato, Valentina Bernasconi, Rodolfo Lanocita, Tommaso Cascella, Melanie Claps, Patrizia Giannatempo, Matteo Zimatore, Laura Cattaneo, Davide Biasoni, Emanuele Montanari, Nicola Nicolai
INTRODUCTION: Surveillance is the standard management in low-risk cN0 penile squamous cell carcinoma (peSCC) patients. However, no previous analysis focused on early and long-term outcomes of these patients. We report on main oncological outcomes of a large series of low-risk cN0 peSCC patients. PATIENTS AND METHODS: Between 1980 and 2017 included, 93 evaluable consecutive low-risk (ie, pT1a G1 cN0M0) peSCC patients underwent primary tumor surgery and either observation (74) or dynamic sentinel node biopsy (DSNB) (19) following a clinical diagnosis of T1 in 66 (71%), T2 in 15 (16...
January 15, 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38296678/impact-of-metastatic-site-in-favorable-risk-renal-cell-carcinoma-receiving-sunitinib-or-pazopanib
#53
JOURNAL ARTICLE
Martina Catalano, Ugo De Giorgi, Davide Bimbatti, Sebastiano Buti, Giuseppe Procopio, Pierangela Sepe, Matteo Santoni, Luca Galli, Raffaele Conca, Laura Doni, Lorenzo Antonuzzo, Giandomenico Roviello
BACKGROUND: Although in metastatic renal cell carcinoma (mRCC) patients with intermediate and poor risk the benefit of combination strategies versus tyrosine kinase inhibitor (TKI) has been ascertained, in those with favorable risk data are ambiguous. Herein, we investigated the impact of number and type of metastatic site in patients with favorable risk to contribute to the best therapeutic choice. MATERIAL AND METHODS: Multicenter data regarding patients with favorable risk mRCC carcinoma receiving first-line TKIs, sunitinib or pazopanib, were retrospectively collected...
January 14, 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38245436/spcs-a-novel-classifier-system-based-on-senescence-axis-regulators-reveals-tumor-microenvironment-heterogeneity-and-guides-frontline-therapy-for-clear-cell-renal-carcinoma
#54
JOURNAL ARTICLE
Aimin Jiang, Ying Liu, Baohua Zhu, Yu Fang, Le Qu, Qiwei Yang, Peng Luo, Chen Cai, Linhui Wang
RATIONALE: The emerging evidence suggested that senescence regulator genes were involved in multi cancers, which may be utilized as new targets for cancers. However, the dysregulation and clinical impact of senescence regulator genes in clear cell renal cell cancer (ccRCC) were still in foggy. METHODS: Using multiomics data from TCGA-KIRC and other datasets, we comprehensively investigated the function of senescence regulator genes in ccRCC. ccRCC patients could be remodeled into 2 significant different groups basing on senescence regulators expression: senescence-pattern cancer subtype1 (SPCS1) and subtype2 (SPCS2)...
January 12, 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38281876/cystic-pelvic-masses-in-men-a-presentation-of-uncommon-cases-and-a-literature-review
#55
REVIEW
Constantin Rieger, David Pfister, Lucas Kastner, Marie-Lisa Eich, Alexander Quaas, Yuri Tolkach, Axel Heidenreich
Unclear cystic masses in the pelvis in male patients are a rare situation and could be of benign or malignant origin. The underlying diseases demand for specific diagnostic and therapeutic approaches. We present a case series of 3 male patients with different clinical symptoms (perineal pain, urinary retention and a large scrotal cyst) related to cystic lesions in the pelvic region. On all patients initial histopathological workup was unclear. All patients underwent surgery with complete resection of the tumor which revealed a broad spectrum of histopathological findings: unusual form of cystic adenocarcinoma of the prostate, malignant transformation of a dysontogenetic cyst, and finally a very rare diagnosis of a malignant tumor of the Cowper gland...
January 11, 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38296679/the-efficacy-of-ketoconazole-containing-regimens-in-castration-resistant-prostate-cancer-a-systematic-review-and-meta-analysis
#56
REVIEW
Obaid Ur Rehman, Zain Ali Nadeem, Eeshal Fatima, Umar Akram, Hiba Imran, Ali Husnain, Arsalan Nadeem, Waqas Rasheed
Castration resistant prostate cancer (CRPC) is a challenging subset of prostate cancer associated with an extensive metastatic profile and high mortality. Ketoconazole is a nonselective steroid 17α-hydroxylase/17,20 lyase (CYP17A1) inhibitor and is employed as a second line treatment option for CRPC with an established efficacy profile in patients. The aim of this study is to assess the efficacy of ketoconazole containing regimens for CRPC in terms of prostate specific antigen (PSA) decline rate using a systematic review and meta-analysis...
January 10, 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38290900/the-ability-of-the-star-cap-staging-system-to-prognosticate-the-risk-of-subsequent-therapies-and-metastases-after-initial-treatment-of-m0-prostate-cancer
#57
JOURNAL ARTICLE
Daeun Sung, Bogdana Schmidt, Jonathan David Tward
INTRODUCTION: The International Staging Collaboration for Prostate Cancer (STAR-CAP) has been proposed as a risk model for prostate cancer with superior prognostic power compared to the current staging system. This study aimed to evaluate the performance of STAR-CAP in predicting the risk of subsequent therapy after initial treatment and the risk of developing metastases. PATIENTS AND METHODS: The study included 3425 men from an institutional observational registry with a median age of 64...
January 9, 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38228414/bladder-preserving-trimodality-therapy-with-capecitabine
#58
JOURNAL ARTICLE
Connor Lynch, Randy F Sweis, Parth Modi, Piyush K Agarwal, Russell Z Szmulewitz, Walter M Stadler, Peter H O'Donnell, Stanley L Liauw, Sean P Pitroda
INTRODUCTION: Many patients with muscle-invasive bladder cancer are poor candidates for radical cystectomy or trimodality therapy with maximal transurethral resection of bladder tumor (TURBT) and chemoradiotherapy with cisplatin or mitomycin C. Given the benefit of chemotherapy in bladder-preserving therapy, less-intense concurrent chemotherapy regimens are needed. This study reports on efficacy and toxicity for patients treated with trimodality therapy using single-agent concurrent capecitabine...
January 9, 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38220540/bladder-cancer-and-the-urinary-microbiome-new-insights-and-future-directions-a-review
#59
REVIEW
Angela E Russo, Areeba Memon, Shahid Ahmed
The presence of a microbiome in the urinary system has been established through recent advancements in technology and investigation of microbial communities in the human body. The study of the taxonomic and genomic ecology of microbial communities has been greatly improved by the use of metagenomics. The research in this area has expanded our understanding of microbial ecosystems and shows that the urinary tract contains over 100 species from over 50 genera, with Lactobacillus, Gardnerella, and Streptococcus being the most common...
January 9, 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38267303/assessing-the-impact-of-percutaneous-nephrostomy-presence-on-neoadjuvant-treatment-quality-in-patients-with-muscle-invasive-bladder-cancer
#60
JOURNAL ARTICLE
Ziv Savin, Roy Mano, Alon Lazarovich, Barak Rosenzweig, Reut Shashar, Azik Hoffman, Ilona Pilosov, Yuval Freifeld, Sagi Arieh Shpitzer, Shay Golan, Ofer Yossepowitch, Mario Sofer
INTRODUCTION: Symptomatic hydronephrosis associated with muscle invasive bladder cancer (MIBC) necessitates percutaneous nephrostomy (PCN) insertion before neoadjuvant chemotherapy (NAC). This study assesses the impact of PCN presence on standard intended NAC quality, its related complications and outcome after radical cystectomy (RC). MATERIALS AND METHODS: The study comprises a retrospective, multicenter cohort of 193 consecutive RCs performed between 2016 and 2019...
January 6, 2024: Clinical Genitourinary Cancer
journal
journal
41208
3
4
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.